1
40
1
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1016/j.ijantimicag.2007.07.038" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/j.ijantimicag.2007.07.038</a>
Pages
S131–134
Volume
30 Suppl 2
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
The development of pharmacokinetically enhanced amoxicillin/clavulanate for the management of respiratory tract infections in adults.
Publisher
An entity responsible for making the resource available
International journal of antimicrobial agents
Date
A point or period of time associated with an event in the lifecycle of the resource
2007
2007-12
Subject
The topic of the resource
Adult; Amoxicillin-Potassium Clavulanate Combination/*administration & dosage/pharmacokinetics/therapeutic use; Anti-Bacterial Agents/*administration & dosage/pharmacokinetics/therapeutic use; Bacteria/*drug effects/isolation & purification; Community-Acquired Infections/*drug therapy/microbiology; Humans; Pneumonia/drug therapy/microbiology; Respiratory Tract Infections/*drug therapy/microbiology; Sinusitis/drug therapy/microbiology
Creator
An entity primarily responsible for making the resource
File Thomas M Jr
Description
An account of the resource
Rising levels of resistance amongst the major respiratory pathogens have compromised empiric antimicrobial therapy. This, coupled with a recent lack in availability of novel classes of antibacterials, has led to a need for new approaches to combat community respiratory tract infections. Bacteriological and clinical efficacy in two trials involving patients with acute bacterial sinusitis and six trials of patients with community-acquired pneumonia has shown that the development of a pharmacokinetically enhanced formulation of amoxicillin/clavulanate (Augmentin SR, available as Augmentin XR in the USA) has allowed amoxicillin/clavulanate to retain its place in the treatment of respiratory tract infections today.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/j.ijantimicag.2007.07.038" target="_blank" rel="noreferrer noopener">10.1016/j.ijantimicag.2007.07.038</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2007
Adult
Amoxicillin-Potassium Clavulanate Combination/*administration & dosage/pharmacokinetics/therapeutic use
Anti-Bacterial Agents/*administration & dosage/pharmacokinetics/therapeutic use
Bacteria/*drug effects/isolation & purification
Community-Acquired Infections/*drug therapy/microbiology
Department of Internal Medicine
File Thomas M Jr
Humans
International journal of antimicrobial agents
NEOMED College of Medicine
Pneumonia/drug therapy/microbiology
Respiratory Tract Infections/*drug therapy/microbiology
Sinusitis/drug therapy/microbiology